NIH Funding Announcements
NCI TO CONTINUE PARTICIPATION IN PA-07-279 AND PA-06-418 (NOT-CA-09-036)
NCI informs all interested applicants that it has re-joined and will continue to participate in funding opportunity announcement (FOA) PA-07-279, entitled "Bioengineering Research Grants (BRG)(R01)," and in FOA PA-06-418, entitled "Exploratory/Developmental Bioengineering Research Grants (EBRG)(R21)," until the FOAs expire on January 8, 2010.
BIOENGINEERING RESEARCH GRANTS (BRG)(R01) (PA-10-009) (MULTIPLE ICS INCLUDING NCI)
Application Due Dates: Standard dates
Participating Institutes and Centers of the NIH invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems.
EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (EBRG) [R21] (PA-10-010)(MULTIPLE ICS INCLUDING NCI)
Application Due Dates: Standard dates
This Funding Opportunity Announcement (FOA) is intended to encourage innovation and high risk/impact bioengineering research in new areas. While minimal or no preliminary data are expected to be described in the application, applications should clearly indicate the significance of the proposed work and that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE (SPORES) IN HUMAN CANCER FOR YEARS 2010, 2011 AND 2012 (P50) (NCI, NIDCR, NINDS)) (PAR-10-003)
Letters of Intent Receipt Dates: December 28, 2009; April 20, 2010; August 21, 2010; December 20, 2010; April 20, 2011; August 20, 2011; December 20, 2011; April 22, 2012; August 20, 2012
Application Receipt Dates: January 28 2010; May 20, 2010; September 21, 2010; January 20, 2011; May 20, 2011; September 20, 2011; January 20, 2012; May 22, 2012; September 20, 2012
For the SPORE, the NCI has adopted the definition of translational cancer research from the report of the Translational Research Working Group (TRWG) of the National Cancer Advisory Board: Translational cancer research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications that reduce cancer incidence, morbidity, and mortality (www.cancer.gov/aboutnci/trwg/finalreport.pdf). The term "clinical applications" is used in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the prevention, early detection, diagnosis, prognosis, and/or treatment of cancer. Translational research in a SPORE must always be based upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. Applications may address cancer in any organ site, but each application must be organ site specific or address cancers that are related. Examples include (but are not limited to) leukemias, lymphomas, myelomas, sarcomas, and cancers of brain, breast, gastrointestinal (GI) system, bladder, kidney, cervical, endometrial, head & neck, lung, ovary, pancreas, prostate, skin, oral cavity & pharynx, eye & orbit, and endocrine system. Applicants are encouraged to consult with the Translational Research Program (TRP, http://trp.cancer.gov) staff members regarding the focus of their application.
CANCER NANOTECHNOLOGY TRAINING CENTERS (CNTCS)(R25) (RFA-CA-09-014)
Letters of Intent Receipt Date(s): November 17, 2009
Application Receipt Date(s): December 17, 2009
This FOA solicits applications for the development of: Cancer Nanotechnology Training Centers (CNTCs) as a component of the NCI Alliance for Nanotechnology in Cancer (The Alliance) (http://nano.cancer.gov). In addition to the CNTCs, the Alliance will consist of the Centers for Cancer Nanotechnology Excellence (CCNEs, as the core of the program infrastructure), platform projects (CNPPs), and a K99/00 career transition program. The CNTCs are designed to establish innovative research education programs supporting the development of a multi-disciplinary nanotechnology workforce capable of pursuing cancer research. The proposed CNTCs should target graduate student and post-doctoral researchers of broad background (in medicine, biology, and other health sciences as well as in the physical sciences, chemistry, and engineering).
PATHWAY TO INDEPENDENCE AWARD IN CANCER NANOTECHNOLOGY RESEARCH (K99/R00) (RFA-CA-09-015)
Application Receipt Date(s): December 17, 2009
This FOA solicits applications for the Pathway to Independence Award (K99/R00) in Cancer Nanotechnology Research. The primary purpose of this Pathway to Independence Award Program is to increase and maintain a strong cohort of new talented investigators focused on research in cancer nanotechnology. The program is designed to facilitate a timely transition from a mentored postdoctoral research position to a stable independent research position with independent research support at an earlier stage than is currently the norm.
NOTICE OF AVAILABILITY OF ADMINISTRATIVE SUPPLEMENTS FOR PARTICIPATION IN STANDARDS DEVELOPMENT PROCESS (NIBIB) (NOT-EB-09-006)
Receipt dates: December 1, 2009; April 1, 2010; August 2, 2010; December 1, 2010; April 1, 2011; August 1, 2011
Supplemental funding is available to NIBIB awards for standards development work. The purpose is to encourage NIBIB-funded investigators to focus on translation of their technologies by ensuring interoperability with other technologies. Participation of NIBIB-funded investigators in standards development work will ensure that their expertise and experience in bioengineering and biomedical imaging contribute to community-adopted standards. Eligible parent grants should have at least 24 months remaining at the time the request is made (R03 and R21 grants are ineligible).
BIOSIGNATURE DISCOVERY FOR PERSONALIZED TREATMENT IN DEPRESSION (U01) (NIMH) (MH-10-040)
Letter of intent due: December 14, 2009
Application receipt date: January 13, 2010
The purpose of this initiative is to support exploratory research to discover panels of promising biomarkers (i.e., biosignatures) that are predictive of treatment outcomes in major depressive disorder.
FUNCTIONAL MODELING OF PEDIATRIC UPPER AIRWAY DISORDERS (R01) (NHLBI)(HL-10-017)
Letters of Intent Receipt Date(s): December 14, 2009
Application Due Date(s): January 12, 2010
To promote collaborative, innovative research that will develop and validate new tools for evaluating/predicting upper airway dysfunction in children. The objective is to identify the biological and structural components creating airflow limitation in congenital or acquired disorders of the pediatric upper airway (infant to adolescent). The program will support the development and validation of computational models using data that measures biological processes such as airflow, inflammatory markers, airway pressures, and data that measures structures (e.g., minimally or non-invasive imaging, endoscopy, optical coherence tomography).
RECOVERY ACT 2009 LIMITED COMPETITION: AHRQ CLINICAL AND HEALTH OUTCOMES INITIATIVE IN COMPARATIVE EFFECTIVENESS (CHOICE) GRANTS (R01)(HS-10-003)
Letters of Intent Receipt Date(s): November 18, 2009
Application Due Date(s): December 16, 2009
This AHRQ Funding Opportunity Announcement (FOA), supported by funds provided to AHRQ under the American Recovery & Reinvestment Act of 2009 ("Recovery Act" or "ARRA"), Public Law 111-5, invites Research Project Grant (R01) applications for large projects in comparative effectiveness aimed at generating new knowledge to help inform decision making in priority areas of clinical care. The impact of these studies should have a high likelihood of creating major advancements in clinical care. Examples of potential projects include Prospective evaluation of the long-term outcomes of new imaging technologies to diagnose or monitor a priority condition.
MORRIS K. UDALL CENTERS OF EXCELLENCE FOR PARKINSONS DISEASE RESEARCH (P50) (RFA-NS-10-001) (NINDS)
Application Receipt Date(s): December 10, 2009
RESTRUCTURED APPLICATION FORMS AND INSTRUCTIONS FOR SUBMISSIONS FOR FY2011 FUNDING
Applicants MUST return to the FOA (or the reissued PARENT ANNOUNCeMENT) to download the new application forms and instructions for due dates on or after January 25, 2010.
New Application Structure and Length (taken from NOT-OD-09-149 announcement)
Shortened Page Limits. The page limit for the new Research Strategy section will be 6 or 12 pages, according to the chart below. One additional page will be allowed for Specific Aims. As always, if the FOA requires page limits that differ from the application instructions, the FOA page limits should be followed. For resubmission and revision applications for most programs, the Introduction will be limited to one page.
Current Page Limit
(Section 2-5 of the Research Plan)
New Page Limit
Follow FOA Instructions
For individual Career Development (K) applications, the Research Strategy includes Candidate Information, and will be limited to 12 pages.
The Program Plan for Institutional Career Development and Research Training (T) Awards, including K12, Ruth L. Kirschstein Institutional NRSA Applications, International Training Program Planning Grants and Grants in Epidemiology (D43 and D71), and Education Projects (R25) remains at 25 pages, or as indicated in specific FOAs. The Introduction to Resubmission Application for Training (T, D43, D71), R25 and K12 applications will be three pages.
Additional detail on changes to page limits for specific sections of the application, organized by activity code, may be found at the Table of Page Limits (http://enhancing-peer-review.nih.gov/page_limits.html ).
Alignment of the Application with Peer Review Criteria. To coordinate with the enhanced peer review criteria, changes will be made to the following sections of the application forms and instructions: 1) Research Plan, 2) Resources, and 3) Biographical Sketch.
Current Research Plan
Restructured Research Plan
1.Introduction to Application (Resubmission or Revision Applications only)
1. Introduction to Application (Resubmission or Revision Applications only)
2. Specific Aims
2. Specific Aims
3. Background and Significance
3. Research Strategy
4. Preliminary Studies/Progress Report
5. Research Design and Methods
6. to 12.
4. to 10. (renumbered)
13. Select Agent Research
11. Select Agent Research (modified)
14. to 17.
12. to 15. (renumbered)
The Biographical Sketch changes are also implemented for the PHS 2590 Noncompeting Continuation Progress Report (Notice OD-09-139), effective October 1, 2009. Although not immediately required in competing applications, institutions may begin to include a Personal Statement and 15 or fewer publications in Biographical Sketches (as described in this Policy Announcement) prior to January 25, 2010 due dates, if desired.
For more details, visit http://enhancing-peer-review.nih.gov/docs/application_changes.pdf
Other Funding Agencies
DOD FY09 Lung Cancer Research Program (LCRP)
Clinician Fellow Research Award
Lung Cancer Promising Clinician Research Award
Collaborative Translational Research Award
Deadlines: Pre-Application: 11/19/09; Proposal: 12/3/09
Lung Cancer Biospecimen Resource Network Award
Deadlines: Pre-Application 12/23/09; Proposal: 1/6/10
Synopsys of LCRP FY09 Award Mechanisms: http://cdmrp.army.mil/funding/09lcrpreftable.htm
NOTICE OF INTENT TO PUBLISH A REQUEST FOR APPLICATIONS FOR NIBIB QUANTUM PROJECTS: IMPLEMENTATION PHASE II (U01) (NOT-EB-09-005)
NIBIB intends to publish an RFA for Phase II of the NIBIB Quantum Program. The Program's goal is to achieve a profound (quantum) impact on the detection, prevention, diagnosis or treatment of a major disease or national public health problem (e.g., leading categories of disease burden, high-mortality/morbidity diseases affecting more than 100,000 individuals annually, technologies that revolutionize over 200,000 procedures annually) through the development and implementation of biomedical technologies.
CLARIFICATION ON THE USE OF AN NIHMSID TO INDICATE COMPLIANCE WITH THE NIH PUBLIC ACCESS POLICY
The NIH Public Access Policy ensures that the public has access to published results of NIH funded research. One requirement of the policy is that institutions submitting an application, proposal or progress report to the NIH must include the PubMed Central (PMC) reference number (PMCID) when citingapplicable papers that are authored by the Principal Investigator (PI) or that arise from the PI's NIH-funded research.
An awardee may demonstrate compliance with the Public Access Policy by including an NIH Manuscript Submission Reference Number (NIHMSID) in lieu of a PMCID at the end of a full citation. The NIHMSID is a temporary substitute for a PMCID when using either Submission Methods C or D under the NIH Public Access Policy. It is intended to be used only in cases where an awardee needs to cite a paper soon after its acceptance by a journal, when there is not enough time to complete every step of the NIH manuscript submission process.
EXTENSION OF MODIFIED APPLICATION SUBMISSION, REFERRAL AND REVIEW FOR REVIEWERS WITH RECENT SUBSTANTIAL SERVICE (NOT-OD-09-155)
As part of the NIH continuing commitment to recognize outstanding review and advisory service, and to minimize disincentives to such service, an alternate plan for submission and review of research grant applications from appointed members of NIH review and advisory groups is being extended to applicants who have performed substantial peer review service. The extension is to individuals who have participated in peer review as regular or temporary members six times in 18 months.
CIP DCIDE PROGRAM MORPHS INTO NExTThe Cancer Imaging Program's DCIDE program for providing data to investigators for their IND filings is being absorbed by the NCI Experimental Therapeutics Program (NExT). On the web site, click on the NExT icon to start submission of a NExT application. The first round of submissions are due September 15, 2009, and quarterly after that starting November 15, 2009. Click on the instructions to see what you need to do to apply. The reviews are to be handled by outside Special Emphasis Panels empanelled for the purpose.
GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at firstname.lastname@example.org. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
Memphis Bioimaging Symposium
November 5-6, 2009, Fogelman Executive Center, University of Memphis, TN
Innovations in Optical Imaging of Cancer
November 12, 2009, UT Southwestern Medical Center, T Boone Pickens Biomedical Building, Dallas, Texas
RSNA 95th Scientific Assembly
November 29- December 4, 2009, McCormick Place, Chicago, IL
RSNA 2010 Clinical Trials Methodology Workshop
January 9-15, 2010, Hyatt Regency, Scottsdale, Arizona
Apply on line by June 8, 2009.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (email@example.com). Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program,
Division of Cancer Treatment and Diagnosis,
NCI 6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507